Nama's AI scorecard currently rates DaVita Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is DVA's P/E ratio?

DaVita trades at a trailing price-to-earnings ratio of 13.6.

When does DVA report earnings?

DaVita's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $4.22.

What is the DVA price target?

The median analyst price target from 7 analysts is $216.00, with a range of $165.00 – $287.00.

Is DVA Shariah compliant?

Nama's AAOIFI-style screen reads DaVita as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

DaVita (DVA)

Healthcare · Medical Care Facilities · NYSE

S&P 500

DaVita (DVA) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $12.04B, a trailing price-to-earnings ratio of 13.6 and a free-cash-flow yield of 9.0%. Over the most recent reported fiscal year, revenue grew 6.5% and free cash flow per share grew 2.8%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +45.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-22.7%

How far the last close sits under the highest price of the past five years.

Market cap	$12.04B
Trailing P/E	13.6
Price / book	—
Price / sales	0.8
FCF yield	9.0%
Dividend yield	—
Gross margin	32.3%
Operating margin	15.2%
Net margin	6.5%
Revenue growth (YoY)	+6.5%
Revenue growth (3-yr annual)	+5.5%
EPS growth (YoY)	+10.8%
FCF/share growth (YoY)	+2.8%
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

DVA earnings

Next report: Feb 1, 2027 (Q4 2026, EPS estimate $4.22). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$3.82	$3.57	+7.0%	$3.58B
Q2 2026	Aug 4, 2026	$4.02	$3.88	+3.6%	$3.55B
Q1 2026	May 5, 2026	$2.87	$2.33	+23.2%	$3.42B
Q4 2025	Feb 2, 2026	$3.40	$3.19	+6.6%	$3.62B

DVA analyst price target

Median target $216.00 from 7 analysts, ranging $165.00 – $287.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1
CHE	Chemed	$6.84B	21.2

Explore live DVA data on Nama Insights →

Recent Congressional trades

DaVita trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Julie Johnson	House	Buy	$1,001 - $15,000	Aug 5, 2026
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Oct 7, 2025
Jerry Moran,	Senate	Buy	$1,001 - $15,000	—

DVA FAQ

Is DVA a buy?: Nama's AI scorecard currently rates DaVita Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is DVA's P/E ratio?: DaVita trades at a trailing price-to-earnings ratio of 13.6.
When does DVA report earnings?: DaVita's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $4.22.
What is the DVA price target?: The median analyst price target from 7 analysts is $216.00, with a range of $165.00 – $287.00.
Is DVA Shariah compliant?: Nama's AAOIFI-style screen reads DaVita as Not Shariah Compliant. At least one of the three ratios or the industry test failed.